Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
As of February 2026 , BPC-157 returned to Category 1 compounding status meaning licensed 503A and 503B compounding pharmacies can legally prepare it under physician prescription
Human safety, efficacy, dosing, and clinical utility havent been established
Genetic predisposition to B12 deficiency, such as intrinsic factor receptor deficiency (ImerslundGrsbeck syndrome) and transcobalamin II deficiency
Semaglutide, the primary combination partner (CagriSema) The most extensively studied combination for Cagrilintide
By enhancing angiogenesis: Nutrients and oxygen reach damaged tissues faster Inflammatory byproducts are cleared more efficiently Regeneration speed increases across soft tissue, joints, and muscle BPC-157 promotes angiogenesis and capillary density in damaged tissues through modulation of VEGF and endothelial nitric oxide synthase (eNOS). Sikiric et al., Regenerative Pharmacology 2
US$ 24.93
US$ 27.09
US$ 28.34
US$ 28.59
US$ 24.52
US$ 21.17
US$ 27.32
US$ 25.60